Expression of an estrogen receptor agonist in differentiating osteoblast cultures

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 19, 2008, Pages 7022-7027

  McCarthy, Thomas L ^a   Clough, Mary E ^a   Gundberg, Caren M ^a   Centrella, Michael ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intracrine; Selective estrogen receptor modulator; Steroid

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR STIMULATING AGENT; HORMONE RECEPTOR STIMULATING AGENT; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA;

AGONIST; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; FETUS; GENE EXPRESSION REGULATION; HORMONE RECEPTOR INTERACTION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG POTENTIATION; METABOLISM; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION; OSTEOBLASTS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 44349141960     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0800085105     Document Type: Article

References (43)

1. Boonyaratanakornkit V, Edwards DP (2007) Receptor mechanisms mediating nongenomic actions of sex steroids. Semin Reprod Med 25:139-153.
2. Syed FA, et al. (2005) Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res 20:1992-2001.
3. Centrella M, McCarthy TL, Chang W, Labaree DC, Hochberg RB (2004) Estren (4-Estren-3alpha,17beta-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional effects through the androgen receptor. Mol Endo 18:1120-1130.
4. Manolagas SC, et al. (2004) Kinase-mediated transcription, activators of nongenotropic estrogen-like signaling (ANGELS), and osteoporosis: A different perspective on the HRT dilemma. Kidney Int Suppl S41-49.
5. Centrella M, Christakos S, McCarthy TL (2004) Skeletal hormones and the C/EBP and Runx transcription factors: Interactions that integrate and redefine gene expression. Gene 342:13-24.
6. Barkhem T, Nilsson S, Gustafsson JA (2004) Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics 4:19-28.
7. McClung MR (2005) The relationship between bone mineral density and fracture risk. Curr Osteoporos Rep 3:57-63.
8. Sorensen MG, Henriksen K, Schaller S, Karsdal MA (2007) Biochemical markers in preclinical models of osteoporosis. Biomarkers 12:266-286.
9. Rosen CJ (2003) The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr 13:25-38.
10. Windahl SH, Andersson G, Gustafsson JA (2002) Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrinol Metab 13:195-200.
11. Windahl SH, et al. (2007) Identification of target cells for the genomic effects of estrogens in bone. Endocrinology 148:5688-5695.
12. McCarthy TL, et al. (1997) 17beta-estradiol potently suppresses cAMP-induced insulin-like growth factor-I gene activation in primary rat osteoblast cultures. J Biol Chem 272:18132-18139.
13. Ray A, Prefontaine KE, Ray P (1994) Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 269:12940-12946.
14. Stein B, Yang MX (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15:4971-4979.
15. Suda T, Nakamura I, Jimi E, Takahashi N (1997) Regulation of osteoclast function. J Bone Miner Res 12:869-879.
16. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC (2007) Quantifying osteoblast and osteocyte apoptosis: Challenges and rewards. J Bone Miner Res 22:1492-1501.
17. Lemay A (2002) The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can 24:711-715.
18. Brand TC, Canby-Hagino E, Thompson IM (2007) Testosterone replacement therapy and prostate cancer: A word of caution. Curr Urol Rep 8:185-189.
19. Raynaud JP (2006) Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 102:261-266.
20. McCarthy TL, Hochberg RB, Labaree DC, Centrella M (2007) 3-ketosteroid reductase activity and expression by fetal rat osteoblasts. J Biol Chem 282:34003-34012.
21. Yanase T, et al. (2003) Aromatase in bone: Roles of Vitamin D3 and androgens. J Steroid Biochem Mol Biol 86:393-397.
22. McCarthy TL, Chang, W-Z, Liu Y, Centrella M (2003) Runx2 integrates estrogen activity in osteoblasts. J Biol Chem 278:43121-43129.
23. Chang W, Parra M, Centrella M, McCarthy TL (2005) Interactions between CCAAT enhancer binding protein delta and estrogen receptor alpha control insulin-like growth factor I (igf1) and estrogen receptor-dependent gene expression in osteoblasts. Gene 345:225-235.
24. Wiren KM, Chapman Evans A, Zhang XW (2002) Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J Endocrinol 175:683-694.
25. Wang Q, et al. (2006) Temporal expression of estrogen receptor alpha in rat bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 347:117-123.
26. Levin ER (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19:1951-1959.
27. McCarthy TL, Centrella M (2001) Local IGF-I expression and bone formation. Growth Horm IGF Res 11:213-219.
28. Welshons WV, Nagel SC, vom Saal FS (2006) Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology 147:S56-S69.
29. Soto AM, Justicia H, Wray JW, Sonnenschein C (1991) p-Nonyl-phenol: An estrogenic xenobiotic released from "modified" polystyrene. Environ Health Perspect 92:167-173.
30. Moreno-Cuevas JE, Sirbasku DA (2000) Estrogen mitogenic action. III. Is phenol red a "red herring"? In Vitro Cell Dev Biol Anim 36:447-464.
31. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA (2005) Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26:465-478.
32. Sims NA, et al. (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30:18-25.
33. Richard S, Zingg HH (1990) The human oxytocin gene promoter is regulated by estrogens. J Biol Chem 265:6098-6103.
34. Gambacciani M, Vacca F (2004) Postmenopausal osteoporosis and hormone replacement therapy. Minerva Med 95:507-520.
35. Armitage M, Nooney J, Evans S (2003) Recent concerns surrounding HRT. Clin Endocrinol 59:145-155.
36. Cheskis BJ, Greger JG, Nagpal S, Freedman LP (2007) Signaling by estrogens. J Cell Physiol 213:610-617.
37. Wilson ME (1998) Regulation of the growth hormone-insulin-like growth factor I axis in developing and adult monkeys is affected by estradiol replacement and supplementation with insulin-like growth factor I. J Clin Endocrinol Metab 83:2018-2028.
38. Balogh A, Kauf E, Vollanth R, Graser G, Klinger G, Oettel M (2000) Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH). Contraception 62:259-269.
39. Filardo EJ, Quinn JA, Frackelton AR, Jr., Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16:70-84.
40. McCarthy TL, Ji C, Chen Y, Kim K, Centrella M (2000) Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3-,5-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts. Endocrinology 141:127-137.
41. Taranta A, et al. (2002) The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30:368-376.
42. McCarthy TL, Centrella M, Canalis E (1988) Further biochemical and molecular characterization of primary rat parietal bone cell cultures. J Bone Miner Res 3:401-408.
43. Carpenter TO, et al. (1998) Osteocalcin production in primary osteoblast cultures derived from normal and Hyp mice. Endocrinology 139:35-43.